



Presentation by
Dr Peter Molloy
Executive Chairman

Annual General Meeting
26 November 2025



Authorised for release by Peter Molloy, Executive Chairman of Firebrick Pharma Limited

The World Needs

Nasodine[®]
Nasal Spray

NOTICE AND DISCLAIMER

This presentation is provided for information purposes only. The information in this presentation is in a summary form, does not purport to be complete and is not intended to be relied upon as advice to investors or other persons. The information contained in this presentation was prepared as of its date, and remains subject to change without notice. This presentation has been provided to you solely for the purpose of giving you background information about Firebrick Pharma Limited (**Firebrick**). This presentation is intended only for those persons to whom it is delivered personally by or on behalf of Firebrick. By attending this presentation, you represent and warrant that (i) if you are in Australia, you are a person to whom an offer of securities may be made without a disclosure document (as defined in the Corporations Act 2001 (Cth) (**Corporations Act**)) on the basis that you are exempt from the disclosure requirements of Part 6D.2 in accordance with Section 708(8) or 708(11) of the Corporations Act; (ii) if you are outside Australia, you are a person to whom an offer and issue of securities can be made outside Australia without registration, lodgement or approval of a formal disclosure document or other filing in accordance with the laws of that foreign jurisdiction. If you are not such a person, you are not entitled to attend this presentation. Please return this document and any copies and do not provide this document to any other person. This presentation is strictly confidential and is intended for the exclusive benefit of the person to which it is presented. It may not be reproduced, disseminated, quoted or referred to, in whole or in part, without the express consent of Firebrick. The recipient shall not disclose any of the information contained in this presentation to any other person without the prior written consent of Firebrick, which may be withheld in its absolute discretion.

No representation or warranty, express or implied, is made as to the accuracy, reliability, completeness or fairness of the information, opinions and conclusions contained in this presentation. Neither Firebrick, its related bodies corporate, shareholders or affiliates, nor any of their respective officers, directors, employees, related bodies corporate, affiliates, agents or advisers makes any representations or warranties that this presentation is complete or that it contains all material information about Firebrick or which a prospective investor or purchaser may require in evaluating a possible investment in Firebrick or an acquisition of its shares. To the maximum extent permitted by law, none of those persons accept any liability, including, without limitation, any liability arising out of fault or negligence for any loss arising from the use of information contained in this presentation or in relation to the accuracy or completeness of the information, statements, opinions or matters, express or implied, contained in, arising out of or derived from, or for omissions from, this presentation.

Certain statements in this presentation may constitute forward-looking statements or statements about future matters that are based upon information known and assumptions made as of the date of this presentation. Forward looking statements can generally be identified by the use of forward looking words such as, “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target” and other similar expressions within the meaning of securities laws of applicable jurisdictions. Indications of, and guidance or outlook on, clinical trials, required regulatory approvals, future earnings or financial position or performance are also forward looking statements. These statements are subject to internal and external risks and uncertainties that may have a material effect on future business. Actual results may differ materially from any future results or performance expressed, predicted or implied by the statements contained in this presentation. As such, undue reliance should not be placed on any forward looking statement. Past performance is not necessarily a guide to future performance. Nothing contained in this presentation nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee, whether as to the past, present or future. No person is under any obligation to update this presentation at any time after its release to you.

The provision of this presentation is not a representation to you or any other person that an offer of securities will be made. Any prospective transaction would be undertaken solely on the basis of disclosure documentation prepared in accordance with applicable securities laws and regulations. The information presented in this presentation may differ materially in both content and presentation from that presented in any disclosure document prepared in connection with any prospective transaction. Firebrick reserves the right to alter the information contained in this presentation in any disclosure document prepared in respect of any prospective transaction from the form of this presentation accordingly.

This presentation is not, and does not constitute, an offer to sell or the solicitation, invitation or recommendation to purchase any securities in Firebrick and neither this presentation nor any of the information contained herein shall form the basis of any contract or commitment. In particular, this presentation does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States.

This presentation may not be reproduced or redistributed to any other person. This is a private communication and was not intended for public circulation or publication or for the use of any third party without the prior approval of Firebrick. All references to dollars, cents or \$ in this presentation are to Australian currency, unless otherwise stated.

In receiving this presentation, each recipient agrees to the foregoing terms and conditions.

Our primary asset: Nasodine® Nasal Spray

- Firebrick successfully developed the world's first clinically-supported povidone-iodine nasal spray, Nasodine® Nasal Spray ("Nasodine").
- *In vitro*, Nasodine kills all known respiratory viruses and bacteria – including pandemic viruses – with no potential for resistance.
- *In vivo*, Nasodine has been proven safe, and shown to be clinically effective in reducing overall cold severity. (Polasek & Friedland, 2025. DOI: [10.3389/fmed.2025.1565069](https://doi.org/10.3389/fmed.2025.1565069))
- R&D development of Nasodine is complete, removing forward R&D risk; our R&D investment over more than 10 years has created a strong IP foundation to now support commercialisation.
- Nasodine is already available in several countries and is marketed as a nasal antiseptic, meeting multiple unmet medical needs for consumers, doctors, hospitals and governments.
- New Nasodine products are coming through, starting with the Nasodine Throat Spray, scheduled for December 2025.



Nasodine packaging available in Singapore and Fiji.
Nasodine is not approved for sale in Australia

2025 achievements

2026 plans

“CY” refers to Calendar Year (Jan-Dec)

“FY” refer to Financial Year (Jul-Jun)

USA

Managed via Firebrick Pharma, Inc. (a wholly-owned US subsidiary)
Nasodine marketed as a 'nasal cleanser'

- CY25 achievements
 - Increased online sales through our US e-commerce platform (nasodine.com).
 - Added distribution through online pharmacy (israelpharm.com/online-pharmacy/nasodine) to expand the customer base and sales
- CY26 plans
 - Launch new US packaging for Nasodine Nasal Spray
 - Launch new US website for nasodine.com
 - Launch Nasodine Throat Spray
 - Engage with with drugstore distribution partners
 - Promotion and sampling to US healthcare professionals
 - Make the US business cash flow positive to avoid any drain on Australian cash reserves



Example of US social media advertising

Singapore

- CY25 achievements
 - Retail distribution through Guardian pharmacies; Nasodine won ‘Best Newcomer’ award
 - Growth in online sales (nasodine-sg.com)
 - Nasodine now available in all government hospitals
 - License agreement with Innorini Life Sciences (“Innorini”): helps reduce Firebrick’s marketing expense and signals future market plans for Malaysia, Brunei and Mauritius
- CY26 plans
 - Expand retail distribution to the Watsons and Unity pharmacy chains
 - Launch Nasodine Throat Spray into HCP & hospital market and retail pharmacy chains



Nasodine packaging available in Singapore and Fiji.



Fiji and South Pacific

- CY25 achievements
 - Executed license agreement with local pharmaceutical partner, Makans Ltd
 - First order received from Makans
 - Promotion of Nasodine to HCPs and distribution started through retail pharmacies in Fiji
 - Promotion to tourists at Nadi airport (nearly 500,000 Australian tourists visit Fiji each year)
- CY26 plans
 - More orders from Makans
 - Expansion of sales through South Pacific
 - Launch of Nasodine Throat Spray



Billboard advertising Nasodine at Nadi International Airport

The Philippines

- CY25 achievements
 - Strategic investment in Firebrick by SV More Pharma Corporation (via Pharma Nutria N.A. Inc.) of \$1.2 million
 - Successful manufacturing of two batches of Nasodine Nasal Spray in March 2025
 - Regulatory approval application expected to be filed in December 2025
- CY26 goals
 - Approval of Nasodine Nasal Spray for marketing by Philippines FDA
 - Preparations for launch of Nasodine Nasal Spray



L-R: Albert-Jan Santillana (President SV More Pharma Corp), Stephen Goodall (COO Firebrick Pharma), Peter Molloy (CEO Firebrick Pharma), Paul Santillana (Vice-President SV More Pharma Corp)

Why the Philippines is important:

- ✓ Large market with population of 120m (20x Singapore and 60x Fiji)
- ✓ Committed, capable marketing partner, SV More Pharma Corporation
- ✓ No manufacturing or marketing costs for Firebrick

Beyond existing Nasodine markets

- Australia
 - We will continue discussions with TGA about potential pathways for approval of Nasodine in Australia
- New Markets
 - We are actively pursuing new markets and partnerships for Nasodine in several countries in Southeast Asia where there is potential for early approvals; we expect announcements about some of these markets and partnerships in CY26
 - We are also exploring partnering opportunities for Nasodine in countries outside Southeast Asia, including the Middle East, East Asia and South Asia

New Products: Nasodine Throat Spray

- Nasodine Throat Spray is the first of several new Nasodine products planned for introduction in CY26
- Features of Nasodine Throat Spray
 - Compact, convenient and less messy alternative to throat gargles
 - Targeted applicator to direct spray to the sore throat area
- Launch plans
 - To be launched in Singapore and Fiji in CY26 and other regional markets thereafter where it is classified as an antiseptic product*



Nasodine Throat Spray packaging available in Singapore and Fiji.
Nasodine Throat Spray is not approved for sale in Australia

* In Australia, like Nasodine Nasal Spray, Nasodine Throat Spray is currently considered a new drug, requiring a full clinical dossier to support its approval as a registered medicine.

Operating costs, funding and board

- Operating costs
 - Despite growing our markets and developing new products, during CY25, we saw no significant growth in our operating cost base and expect it to remain at a similar level in CY26
- Funding
 - In CY25, we received \$250,000 in R&D tax incentive income and with ongoing product development programs that qualify for the RDTI, we expect a similar level of RDTI income in CY26
 - We raised \$1.6 million in placement funds and \$1.2 million in strategic investments from our Philippines strategic partner (Pharma Nutria N.A. Inc.)
- Board
 - In November 2025, the Board has hired a professional executive search firm to recruit a new non-executive director to join the board to replace the vacancy created by the unfortunate passing of Dr Phyllis Gardner in September 2025. We expect to have more information on the outcome of the search in the New Year

Shareholder Sentiment & Nasodine User Feedback


Results of surveys conducted in October and November
2025

Shareholder Sentiment Survey

- At 11 November 2025, Firebrick had nearly 3,800 registered shareholder accounts representing an estimated 3,575 individual shareholders, based on common addresses
- At that time, we had email contact details for around 1,270 of the individual shareholders (35.5% of total)
- On 13 November 2025, we emailed these shareholders (excluding company employees, family members and other insiders), asking them to complete a survey about Firebrick
- The goal was to obtain feedback on how Firebrick is perceived as a public company, and how we are performing overall
- 145 shareholders (11.4%) responded and provided valuable feedback, which we are pleased to share with all shareholders


Shareholder Sentiment Survey

How does Firebrick perform as a public company?




Shareholder Sentiment Survey

Goals for the next 12 months




Shareholder Sentiment Survey

What are the most important attributes of Nasodine to shareholders?



Shareholder Sentiment Survey



Shareholder Sentiment Survey


Shareholder comments – summary of key feedback

- Positive
 - Many shareholders commented about the openness of the company and its willingness to engage with shareholders, including through regular email updates and HotCopper
 - Many also appreciated the challenges of the past and applauded the company's resilience in the face of those and strongly supported Firebrick's current strategy
- Negative
 - Almost all the negative comments related to the share price; concerns were most acutely expressed by smaller shareholders who bought shares immediately after the IPO in 2022 when the share price was around 10-fold higher than current levels
 - The Company remains fully committed to building shareholder value and providing positive long term returns for all shareholders
- All comments made on the survey that invite or need a response (and where an email address is available) will be individually responded to by the Executive Chairman


Nasodine User Survey

- In addition to the shareholder survey, we recently conducted a Nasodine user survey to gain insights into verified users' experiences with Nasodine
- Around 850 Australians have now purchased Nasodine from Singapore for their personal use in the past 12 months
- In October 2025, we emailed these users a survey to hear about their experiences with Nasodine Nasal Spray in the 'real world'
- 300 users completed the survey
- The results of that survey revealed interesting and positive views about Nasodine's efficacy and safety, and its breadth of usage



Why did you decide to use Nasodine?



What did you use Nasodine for?



For your most frequent use, how would you rate Nasodine's EFFECTIVENESS and EASE OF USE?



Key findings from the user survey

- In a post-COVID world, the fact that Nasodine kills all respiratory viruses and can be used to protect people from respiratory illness, are very strong attractions to the product
- The fact that it has been clinically proven to be safe and is supported by peer-reviewed published studies are also major features
- 85-90% of the use of Nasodine is for treating and preventing colds and flu (as expected), but there are additional uses that are important to some people, such as sinusitis and COVID
- The survey confirmed that users believe Nasodine to be very effective and easy to use
- These findings augur well for the adoption of Nasodine in all future markets

In closing...

- Firebrick has a clear sense of its purpose, direction and priorities
- Firebrick understands the needs of its shareholders and will strive to meet those needs and continue to communicate openly and honestly with all shareholders
- Nasodine is not currently available in Australian pharmacies and Firebrick will continue to pursue local approval
- In the meantime, a growing number of Australians (including shareholders) are buying Nasodine from the Nasodine Singapore website and using the product. Their experiences confirm that Nasodine is a highly effective and easy-to-use treatment and preventative for the common cold, which is a positive indicator for adoption in new markets